{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:31:28Z","timestamp":1787689888588,"version":"build-2784847793"},"reference-count":100,"publisher":"American Diabetes Association","issue":"8","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:p>In combatting the obesity crisis, leveraging mechanisms that lower body weight is critical. The finding that treatment with tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist, produces profound weight loss highlights the value of activating the incretin receptors. Supporting this, recent studies have revealed mechanisms by which GIP receptor (GIPR) activation is beneficial in pancreatic islets, the central nervous system (CNS), and adipose tissue. Paradoxically, a hypothesis has emerged that GIPR antagonism could be an additional option in treating obesity. This concept stems from concern that GIP facilitates lipid uptake and storage in adipose tissue, although the lipid-buffering capacity of adipocytes versus other cell types is metabolically favorable. In this article, we highlight the natural physiology of the incretins, noting GIP as the primary incretin. In the CNS, GIPR agonism attenuates nausea and suppresses appetite, features that also help GLP-1 receptor agonism promote a negative energy balance. Further, we provide rationale that, in protecting against ectopic fat distribution and augmenting substrate utilization to promote insulin sensitivity, GIPR activity in adipose tissue is advantageous. Collectively, these attributes support GIPR agonism in the treatment of obesity and metabolic disease.<\/jats:p>","DOI":"10.2337\/dbi24-0026","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T09:01:58Z","timestamp":1750064518000},"page":"1326-1333","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":10,"title":["A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity"],"prefix":"10.2337","volume":"74","author":[{"given":"Ricardo J.","family":"Samms","sequence":"first","affiliation":[{"name":"Diabetes, Obesity and Complications, Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6748-9929","authenticated-orcid":false,"given":"Kyle W.","family":"Sloop","sequence":"additional","affiliation":[{"name":"Diabetes, Obesity and Complications, Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"2026061114070730100_B1","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1210\/endo.133.6.8243312","article-title":"Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain","volume":"133","author":"Usdin","year":"1993","journal-title":"Endocrinology"},{"key":"2026061114070730100_B2","doi-asserted-by":"crossref","first-page":"REVIEWS3013","DOI":"10.1186\/gb-2001-2-12-reviews3013","article-title":"Family-B G-protein-coupled receptors","volume":"2","author":"Harmar","year":"2001","journal-title":"Genome Biol"},{"key":"2026061114070730100_B3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2026061114070730100_B4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/00063030-199912020-00007","article-title":"Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency","volume":"12","author":"Prakash","year":"1999","journal-title":"BioDrugs"},{"key":"2026061114070730100_B5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/1756283X11436318","article-title":"Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome","volume":"5","author":"Jeppesen","year":"2012","journal-title":"Therap Adv Gastroenterol"},{"key":"2026061114070730100_B6","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/jm9909645","article-title":"Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration","volume":"43","author":"Knudsen","year":"2000","journal-title":"J Med Chem"},{"key":"2026061114070730100_B7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/dmrr.1080","article-title":"Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein","volume":"26","author":"Glaesner","year":"2010","journal-title":"Diabetes Metab Res Rev"},{"key":"2026061114070730100_B8","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem"},{"key":"2026061114070730100_B9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"key":"2026061114070730100_B10","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nm727","article-title":"Inhibition of gastric inhibitory polypeptide signaling prevents obesity","volume":"8","author":"Miyawaki","year":"2002","journal-title":"Nat Med"},{"key":"2026061114070730100_B11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","article-title":"Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes","volume":"52","author":"H\u00f8jberg","year":"2009","journal-title":"Diabetologia"},{"key":"2026061114070730100_B12","first-page":"108","author":"Alsina-Fernandez","year":"2016"},{"key":"2026061114070730100_B13","first-page":"65","author":"Alsina-Fernandez","year":"2011"},{"key":"2026061114070730100_B14","author":"Alsina-Fernandez","year":"2020"},{"key":"2026061114070730100_B15","first-page":"54","author":"Dimarchi","year":"2010"},{"key":"2026061114070730100_B16","first-page":"92","author":"Hogendorf","year":"2019"},{"key":"2026061114070730100_B17","first-page":"31","author":"Asami","year":"2018"},{"key":"2026061114070730100_B18","doi-asserted-by":"crossref","first-page":"209ra151","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Sci Transl Med"},{"key":"2026061114070730100_B19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"2026061114070730100_B20","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"2026061114070730100_B21","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"2026061114070730100_B22","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"2026061114070730100_B23","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1210\/endo-99-3-780","article-title":"The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas","volume":"99","author":"Pederson","year":"1976","journal-title":"Endocrinology"},{"key":"2026061114070730100_B24","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 7-36: a physiological incretin in man","volume":"2","author":"Kreymann","year":"1987","journal-title":"Lancet"},{"key":"2026061114070730100_B25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0014-5793(87)81430-8","article-title":"Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut","volume":"211","author":"Holst","year":"1987","journal-title":"FEBS Lett"},{"key":"2026061114070730100_B26","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1210\/jcem-37-5-826","article-title":"Stimulation of insulin secretion by gastric inhibitory polypeptide in man","volume":"37","author":"Dupre","year":"1973","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061114070730100_B27","doi-asserted-by":"crossref","first-page":"8641","DOI":"10.1073\/pnas.89.18.8641","article-title":"Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1","volume":"89","author":"Thorens","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026061114070730100_B28","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.2337\/diab.44.10.1202","article-title":"Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor","volume":"44","author":"Gremlich","year":"1995","journal-title":"Diabetes"},{"key":"2026061114070730100_B29","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2337\/diabetes.53.5.1326","article-title":"Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors","volume":"53","author":"Hansotia","year":"2004","journal-title":"Diabetes"},{"key":"2026061114070730100_B30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"2026061114070730100_B31","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.2337\/db14-1751","article-title":"GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: the ADDITION-PRO study","volume":"64","author":"F\u00e6rch","year":"2015","journal-title":"Diabetes"},{"key":"2026061114070730100_B32","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jcem.86.8.7750","article-title":"Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients","volume":"86","author":"Toft-Nielsen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061114070730100_B33","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.2337\/db07-0100","article-title":"Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state","volume":"56","author":"Knop","year":"2007","journal-title":"Diabetes"},{"key":"2026061114070730100_B34","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00401145","article-title":"Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients","volume":"36","author":"Nauck","year":"1993","journal-title":"Diabetologia"},{"key":"2026061114070730100_B35","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00125-002-1028-x","article-title":"Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob\/ob) mice: evidence that GIP is the major physiological incretin","volume":"46","author":"Gault","year":"2003","journal-title":"Diabetologia"},{"key":"2026061114070730100_B36","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2337\/db18-1123","article-title":"Separate and combined glucometabolic effects of Endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals","volume":"68","author":"Gasbjerg","year":"2019","journal-title":"Diabetes"},{"key":"2026061114070730100_B37","doi-asserted-by":"crossref","first-page":"170176","DOI":"10.1016\/j.peptides.2019.170176","article-title":"No evidence of tachyphylaxis for insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) in subjects with type 2 diabetes, their first-degree relatives, or in healthy subjects","volume":"125","author":"Nauck","year":"2020","journal-title":"Peptides"},{"key":"2026061114070730100_B38","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"2026061114070730100_B39","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1210\/jc.2014-4009","article-title":"\u03b2-Cell sensitivity to GLP-1 in healthy humans is variable and proportional to insulin sensitivity","volume":"100","author":"Aulinger","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061114070730100_B40","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s42255-023-00811-0","article-title":"The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets","volume":"5","author":"El","year":"2023","journal-title":"Nat Metab"},{"key":"2026061114070730100_B41","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2026061114070730100_B42","doi-asserted-by":"crossref","first-page":"101915","DOI":"10.1016\/j.molmet.2024.101915","article-title":"Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice","volume":"83","author":"Akindehin","year":"2024","journal-title":"Mol Metab"},{"key":"2026061114070730100_B43","doi-asserted-by":"crossref","first-page":"R885","DOI":"10.1152\/ajpregu.00520.2015","article-title":"GLP-1 and weight loss: unraveling the diverse neural circuitry","volume":"310","author":"Kanoski","year":"2016","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2026061114070730100_B44","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dbi21-0002","article-title":"GIPR function in the central nervous system: implications and novel perspectives for GIP-based therapies in treating metabolic disorders","volume":"70","author":"Samms","year":"2021","journal-title":"Diabetes"},{"key":"2026061114070730100_B45","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cmet.2021.01.015","article-title":"The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling","volume":"33","author":"Zhang","year":"2021","journal-title":"Cell Metab"},{"key":"2026061114070730100_B46","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cmet.2019.07.013","article-title":"Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake","volume":"30","author":"Adriaenssens","year":"2019","journal-title":"Cell Metab"},{"key":"2026061114070730100_B47","doi-asserted-by":"crossref","first-page":"106022","DOI":"10.1016\/j.appet.2022.106022","article-title":"A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus","volume":"174","author":"Smith","year":"2022","journal-title":"Appetite"},{"key":"2026061114070730100_B48","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.164921","article-title":"Hypothalamic and brainstem glucose-dependent insulinotropic polypeptide receptor neurons employ distinct mechanisms to affect feeding","volume":"8","author":"Adriaenssens","year":"2023","journal-title":"JCI Insight"},{"key":"2026061114070730100_B49","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.2337\/db17-1385","article-title":"Liraglutide modulates appetite and body weight through glucagon-like peptide 1 receptor\u2013expressing glutamatergic neurons","volume":"67","author":"Adams","year":"2018","journal-title":"Diabetes"},{"key":"2026061114070730100_B50","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2337\/db21-0459","article-title":"GIP receptor agonism attenuates GLP-1 receptor agonist\u2013induced nausea and emesis in preclinical models","volume":"70","author":"Borner","year":"2021","journal-title":"Diabetes"},{"key":"2026061114070730100_B51","doi-asserted-by":"crossref","first-page":"101407","DOI":"10.1016\/j.molmet.2021.101407","article-title":"Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation","volume":"55","author":"Costa","year":"2022","journal-title":"Mol Metab"},{"key":"2026061114070730100_B52","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/s42255-023-00931-7","article-title":"Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice","volume":"5","author":"Liskiewicz","year":"2023","journal-title":"Nat Metab"},{"key":"2026061114070730100_B53","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.2337\/db21-0848","article-title":"GIPR agonism inhibits PYY-induced nausea-like behavior","volume":"71","author":"Samms","year":"2022","journal-title":"Diabetes"},{"key":"2026061114070730100_B54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molmet.2018.12.001","article-title":"Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism","volume":"20","author":"Mroz","year":"2019","journal-title":"Mol Metab"},{"key":"2026061114070730100_B55","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.cmet.2024.06.012","article-title":"Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor","volume":"36","author":"Regmi","year":"2024","journal-title":"Cell Metab"},{"key":"2026061114070730100_B56","doi-asserted-by":"crossref","first-page":"102074","DOI":"10.1016\/j.molmet.2024.102074","article-title":"Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss","volume":"95","author":"Wean","year":"2025","journal-title":"Mol Metab"},{"key":"2026061114070730100_B57","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bph.15647","article-title":"Glucagon-like peptide-1 in diabetes care: can glycaemic control be achieved without nausea and vomiting","volume":"179","author":"Borner","year":"2022","journal-title":"Br J Pharmacol"},{"key":"2026061114070730100_B58","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2026061114070730100_B59","doi-asserted-by":"crossref","first-page":"E528","DOI":"10.1152\/ajpendo.00330.2023","article-title":"The antiemetic actions of GIP receptor agonism","volume":"326","author":"Borner","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026061114070730100_B60","doi-asserted-by":"crossref","first-page":"101743","DOI":"10.1016\/j.molmet.2023.101743","article-title":"GIP receptor agonism blocks chemotherapy-induced nausea and vomiting","volume":"73","author":"Borner","year":"2023","journal-title":"Mol Metab"},{"key":"2026061114070730100_B61","doi-asserted-by":"crossref","first-page":"110953","DOI":"10.1016\/j.celrep.2022.110953","article-title":"A brainstem circuit for nausea suppression","volume":"39","author":"Zhang","year":"2022","journal-title":"Cell Rep"},{"key":"2026061114070730100_B62","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1111\/dom.15875","article-title":"A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy","volume":"26","author":"Knop","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026061114070730100_B63","doi-asserted-by":"crossref","DOI":"10.2337\/db23-56-OR","article-title":"56-OR: a long-acting glucose-dependent insulinotropic polypeptide receptor agonist shows weight loss without nausea or vomiting","volume":"72","author":"Knop","year":"2023","journal-title":"Diabetes"},{"key":"2026061114070730100_B64","doi-asserted-by":"crossref","first-page":"E472","DOI":"10.1152\/ajpendo.00250.2023","article-title":"Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss","volume":"326","author":"Buller","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026061114070730100_B65","doi-asserted-by":"crossref","article-title":"Human HYPOMAP: a comprehensive spatio-cellular map of the human hypothalamus","author":"Tadross","DOI":"10.1101\/2023.09.15.557967"},{"key":"2026061114070730100_B66","article-title":"Glucose-dependent insulinotropic polypeptide receptor signalling in oligodendrocytes increases the weight loss action of GLP-1R agonism","author":"Hansford","journal-title":"Cell Metab"},{"key":"2026061114070730100_B67","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s42255-023-00966-w","article-title":"A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"V\u00e9niant","year":"2024","journal-title":"Nat Metab"},{"key":"2026061114070730100_B68","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/s42255-024-01061-4","article-title":"Characterization of genetic variants of GIPR reveals a contribution of \u03b2-arrestin to metabolic phenotypes","volume":"6","author":"Kizilkaya","year":"2024","journal-title":"Nat Metab"},{"key":"2026061114070730100_B69","doi-asserted-by":"crossref","first-page":"101139","DOI":"10.1016\/j.molmet.2020.101139","article-title":"Targeting the GIPR for obesity: to agonize or antagonize? Potential mechanisms","volume":"46","author":"Campbell","year":"2021","journal-title":"Mol Metab"},{"key":"2026061114070730100_B70","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/dom.15365","article-title":"Improvements in post-challenge lipid response following tirzepatide treatment in patients with type 2 diabetes","volume":"26","author":"Mather","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026061114070730100_B71","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1210\/clinem\/dgae319","article-title":"Effects of tirzepatide vs semaglutide on \u03b2-cell function, insulin sensitivity, and glucose control during a meal test","volume":"109","author":"Mather","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061114070730100_B72","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061114070730100_B73","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00125-002-0873-y","article-title":"Adipose tissue as a buffer for daily lipid flux","volume":"45","author":"Frayn","year":"2002","journal-title":"Diabetologia"},{"key":"2026061114070730100_B74","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1017\/S0029665118002598","article-title":"Turning over our fat stores: the key to metabolic health Blaxter Award Lecture 2018","volume":"78","author":"Frayn","year":"2019","journal-title":"Proc Nutr Soc"},{"key":"2026061114070730100_B75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2337\/db10-0867","article-title":"Downregulation of adipose tissue fatty acid trafficking in obesity: a driver for ectopic fat deposition","volume":"60","author":"McQuaid","year":"2011","journal-title":"Diabetes"},{"key":"2026061114070730100_B76","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/978-3-031-63657-8_8","article-title":"Adipose tissue dysfunction determines lipotoxicity and triggers the metabolic syndrome: current challenges and clinical perspectives","volume":"1460","author":"Carobbio","year":"2024","journal-title":"Adv Exp Med Biol"},{"key":"2026061114070730100_B77","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.bbalip.2009.12.006","article-title":"Adipose tissue expandability, lipotoxicity and the metabolic syndrome--an allostatic perspective","volume":"1801","author":"Virtue","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"2026061114070730100_B78","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2021.12.012","article-title":"Why does obesity cause diabetes","volume":"34","author":"Klein","year":"2022","journal-title":"Cell Metab"},{"key":"2026061114070730100_B79","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cmet.2024.11.003","article-title":"The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice","volume":"37","author":"Yu","year":"2025","journal-title":"Cell Metab"},{"key":"2026061114070730100_B80","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/db21-1166","article-title":"GIPR is predominantly localized to nonadipocyte cell types within white adipose tissue","volume":"71","author":"Campbell","year":"2022","journal-title":"Diabetes"},{"key":"2026061114070730100_B81","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s41586-022-04518-2","article-title":"A single-cell atlas of human and mouse white adipose tissue","volume":"603","author":"Emont","year":"2022","journal-title":"Nature"},{"key":"2026061114070730100_B82","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.molmet.2019.08.006","article-title":"Physiological roles of the GIP receptor in murine brown adipose tissue","volume":"28","author":"Beaudry","year":"2019","journal-title":"Mol Metab"},{"key":"2026061114070730100_B83","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1055\/s-2007-1003745","article-title":"Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride responses in rats","volume":"23","author":"Ebert","year":"1991","journal-title":"Horm Metab Res"},{"key":"2026061114070730100_B84","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1210\/jc.2016-1933","article-title":"Insulin plays a permissive role for the vasoactive effect of GIP regulating adipose tissue metabolism in humans","volume":"101","author":"Asmar","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061114070730100_B85","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1038\/s41467-020-18751-8","article-title":"Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism","volume":"11","author":"Killion","year":"2020","journal-title":"Nat Commun"},{"key":"2026061114070730100_B86","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.2337\/db10-0098","article-title":"Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans","volume":"59","author":"Asmar","year":"2010","journal-title":"Diabetes"},{"key":"2026061114070730100_B87","doi-asserted-by":"crossref","first-page":"E224","DOI":"10.1152\/ajpendo.00347.2016","article-title":"Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response","volume":"312","author":"Thondam","year":"2017","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026061114070730100_B88","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1038\/nutd.2016.15","article-title":"The blunted effect of glucose-dependent insulinotropic polypeptide in subcutaneous abdominal adipose tissue in obese subjects is partly reversed by weight loss","volume":"6","author":"Asmar","year":"2016","journal-title":"Nutr Diabetes"},{"key":"2026061114070730100_B89","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.4049\/jimmunol.1401149","article-title":"Long-acting glucose-dependent insulinotropic polypeptide ameliorates obesity-induced adipose tissue inflammation","volume":"193","author":"Varol","year":"2014","journal-title":"J Immunol"},{"key":"2026061114070730100_B90","doi-asserted-by":"crossref","first-page":"43062","DOI":"10.1074\/jbc.M111.289009","article-title":"Gastric inhibitory peptide controls adipose insulin sensitivity via activation of cAMP-response element-binding protein and p110\u03b2 isoform of phosphatidylinositol 3-kinase","volume":"286","author":"Mohammad","year":"2011","journal-title":"J Biol Chem"},{"key":"2026061114070730100_B91","doi-asserted-by":"crossref","first-page":"8557","DOI":"10.1074\/jbc.M609088200","article-title":"Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade","volume":"282","author":"Kim","year":"2007","journal-title":"J Biol Chem"},{"key":"2026061114070730100_B92","first-page":"E603","article-title":"GIP increases insulin receptor affinity and cellular sensitivity in adipocytes","volume":"249","author":"Starich","year":"1985","journal-title":"Am J Physiol"},{"key":"2026061114070730100_B93","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/s12276-024-01263-6","article-title":"The role of BCAA metabolism in metabolic health and disease","volume":"56","author":"Choi","year":"2024","journal-title":"Exp Mol Med"},{"key":"2026061114070730100_B94","doi-asserted-by":"crossref","first-page":"101550","DOI":"10.1016\/j.molmet.2022.101550","article-title":"Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue","volume":"64","author":"Samms","year":"2022","journal-title":"Mol Metab"},{"key":"2026061114070730100_B95","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.cmet.2012.01.024","article-title":"Interplay between lipids and branched-chain amino acids in development of insulin resistance","volume":"15","author":"Newgard","year":"2012","journal-title":"Cell Metab"},{"key":"2026061114070730100_B96","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/clinem\/dgab722","article-title":"Effects of tirzepatide, a dual GIP and GLP-1 RA, on lipid and metabolite profiles in subjects with type 2 diabetes","volume":"107","author":"Pirro","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061114070730100_B97","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146353","article-title":"GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice","volume":"131","author":"Samms","year":"2021","journal-title":"J Clin Invest"},{"key":"2026061114070730100_B98","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/db23-0172","article-title":"GIPR agonism enhances TZD-induced insulin sensitivity in obese IR mice","volume":"73","author":"Furber","year":"2024","journal-title":"Diabetes"},{"key":"2026061114070730100_B99","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.2337\/dc06-2544","article-title":"Effect of BMI on lifetime risk for diabetes in the U.S","volume":"30","author":"Narayan","year":"2007","journal-title":"Diabetes Care"},{"key":"2026061114070730100_B100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1146\/annurev-publhealth-090419-102644","article-title":"Prediabetes and what it means: the epidemiological evidence","volume":"42","author":"Echouffo-Tcheugui","year":"2021","journal-title":"Annu Rev Public Health"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/74\/8\/1326\/823479\/dbi240026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/74\/8\/1326\/823479\/dbi240026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:07:26Z","timestamp":1781201246000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/74\/8\/1326\/160596\/A-Contemporary-Rationale-for-Agonism-of-the-GIP"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":100,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,6,16]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dbi24-0026","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]}}}